(1) Drug introduction

Adalimumab is a whole-human IgG1 monoclonal antibody against TNF- that binds to soluble and transmembrane TNF- molecules on the cell membrane surface. It blocks TNF- binding to TNF- receptors on the cell surface, resulting in the loss of TNF- biological activity. The biological activity of TNF- is involved in the pathogenesis of psoriasis and contributes a lot to the clinical symptoms.

(2) Suitable for treating people

Severe plaque psoriasis

Adamumab is recommended for the treatment of moderate and severe plaque psoriasis as follows: initial dose of 80mg, subcutaneous injection, 40mg at week 2, and 40mg every 2 weeks thereafter. The effect is apparent 2 weeks after treatment, and the best effect is generally achieved at 12 to 16 weeks. The drug should be discontinued if the improvement does not meet the effective target at week 16 of treatment, or if serious adverse reactions occur during treatment.

Arthropathic psoriasis

Usage similar to plaque psoriasis. The drug should be discontinued after 12 weeks if the disease does not improve as effectively or if there are serious adverse reactions during treatment (such as an infection requiring antibiotic treatment), pregnancy, or surgery.

Other types of psoriasis treatment (pustular type, erythroderma type, etc.)

Because pustular type, erythroderma type incidence rate is low, lack of treatment experience, is not recommended at present.

(3) Therapeutic conversion

With Infliximab.

(4) Combined with other systemic treatments

The combination of adamumab and methotrexate can reduce the immunogenic effect of adamumab and improve its curative effect, while the adverse drug reactions did not increase.

(5) Treatment for special groups (children, pregnancy, breastfeeding, perioperative period, chronic hepatitis B, Hepatitis C, HIV patients, herpes, vaccines, etc.)

In addition to children patients, adamumab in the above special population is usually strictly controlled, cautious use or not.

(6) Pre-treatment screening program

With Infliximab.

(7) Adverse drug reactions

The common adverse reactions were upper respiratory tract infection, nasopharyngitis, headache and cellulitis.

(8) Main screening items in treatment

With Infliximab.

(9) Contraindication

With Infliximab.